Several studies have implied an association between Chlamydic pneumoni
ae (C. pneumoniae) and cardiovascular disease. Our study was designed
to determine whether this organism is associated with severe essential
hypertension in a multiracial British population. Antibodies to C. pn
eumoniae were measured by microimmunofluorescence in 123 patients with
chronic severe hypertension and 123 control subjects, matched for eth
nic origin, age, sex, and smoking habit, admitted to the same hospital
with various noncardiovascular, nonpulmonary disorders. Previous infe
ction was defined by IgG 64 to 256, provided that there was no detecta
ble IgM. Multiple regression analyses of matched and unmatched data we
re used to investigate the influences of antibody levels and potential
confounding factors (ethnic origin, age, sex, smoking habit, diabetes
mellitus, and social deprivation) on hypertension. A portion of the h
ypertensive patients underwent echocardiography, estimation of left ve
ntricular mass index, and measurements of fibrinogen, D-dimer, and von
Willebrand factor concentrations. Thirty-five percent of hypertensive
patients and 17.9% of matched control subjects had antibody titers co
nsistent with previous C. pneumoniae infection. The hypertensive patie
nts differed significantly from their matched control subjects in thei
r level of previous infection, with an odds ratio of 2.5 (95% confiden
ce interval, 1.3 to 4.7). There were no significant differences in ant
ibody levels between patients with left ventricular hypertrophy and th
ose without it. Fibrinogen, D-dimer, and iron Willebrand factor concen
trations were not significantly associated with antibody levels. These
data support an association of C. pneumoniae with severe essential hy
pertension. They provide no evidence of a predisposition to develop le
ft ventricular hypertrophy in hypertensive patients with C. pneumoniae
infection or of associations with hypercoagulability or endothelial d
ysfunction.